up protherics
06 Sep 2016
Cyprotex Website The vacancies under the career section seem to be on the decline.. Hopefully business has not tailed off.I would be interested in any ones view on
up protherics
02 Sep 2016
SBS Interesting write up on the ADVFN board.SBS ( Source Bioscience has been taken private by Trident. .Personally I hope this does not happen here.. Any premium from this level would probably only take the price to 1.70Also the strategic review must be coming to an end soon.. So I would imagine that we will get an answer soon.
Ambiorix1
05 Aug 2016
ORYX moves again ? INGRAM's stockinvest linked to Oryx international growth fund ???The web states Stockinvest LTD dissolved ???Let's dig. More information is welcome.Ambiorix.
Ambiorix1
04 Aug 2016
Famous investor on bord Richard Koch more than 5%...Something up soon or in a few months?Ambiorix.
up protherics
02 Aug 2016
Re: Very nice Trading update Agree.. Excellent results and nothing hidden.Just a huge shame that the company is still saddled with this ridiculous loan agreement.Hopefully the lenders will do an honourable thing and renegotiate,
Ambiorix1
02 Aug 2016
Re: Very nice Trading update Well, here it is. This is what I call a very nice update...Ambiorix.
up protherics
08 Jul 2016
Trading update Hopefully we will get a positive trading update soon to cover the past six months. What would be really good if they announce some sort of buy back for the loan notes.
Carefully Does It
21 Jun 2016
Re: Alert The market usually knows before the rest of us so the rise is probably on the back of the review and whatever is next. CRX is a lovely little company and deserves a re-create.
up protherics
21 Jun 2016
Alert A nice steady rise during the past couple of months. Hopefully this is on the back of fundamentals and not the spiv brigade.Unfortunately they have appeared on some other bulletin boards though with their innate comments.
up protherics
10 Jun 2016
Source Bioscience Harwood capital have launched a bid for Source Bioscience..Which I would imagine would take it private.INMO this going to happen to Cyprotex. Which at the current share price we would be looking at a takeover at around 1.30..Which is only a 20% premium, if their offer for SBS is anything to go by
up protherics
05 Jun 2016
Invitro Toxicology Testing Good link below predicting that the Invitro Toxicology market is set to grow to US 27 billion by 2021. Cyprotex is mentioned as one of the major players.[link]
up protherics
27 May 2016
Re: US Toxic Bill If I have read this right. Only 200 toxic chemicals in the states have been tested for safety out of 80,000 currently on the market.Hopefully Cyprotex will benefit by this.. Also has anyone any news on the strategic review, It would be nice to see all or part of the loan notes repaid
up protherics
26 May 2016
US Toxic Bill The US during the past 24 hrs has past the new toxic subsetence bill. Which will go to the president for final signature. This inmo is fantastic news for Cyprotex I would be interested in any ones views on
Carefully Does It
17 May 2016
Possible? FDA approval is the main target of most Pharma once efficacy and toxicology confirmed. I wonder if there would be a chance of CRX being the predator and not the prey.Buy something like INS on the issue of more shares and somehow satisfy the CLN's and have tox to FDA route in one company.Anything could happen and not just a sale or merger.
biswell2
17 May 2016
Another New RNS but what about IP? No mention in this RNS as to if this new chemPK2 development comes under the banner ofNew IP and is thus protected from copying by others If it could be made 'protected' it's value would be most likley considerableA good development and one that was most likely done with the help of a much bigger company as was indicated when chemPK1 version was launched.There is a refreshing release of new developments of late which I hope continues at the same pace .17th May 2016Cyprotex PLCLaunch of New Enhanced Version of chemPKTM Workflow Solutionfor Predicting Human Pharmacokinetics Directly from Chemical Structure Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of version 2 of its in silico modelling solution, chemPKTM, which predicts human pharmacokinetics directly from chemical structure. Pharmacokinetics is defined as the study of the concentration of a drug or chemical in the body over time, and is related to its absorption, distribution, metabolism and excretion. Understanding the pharmacokinetics is important for understanding the efficacy (effectiveness) or potential toxicity of drugs or chemicals following their administration. The original version of chemPKTM was able to predict human pharmacokinetics following administration of a single oral dose. Version 2 now has the ability to predict human pharmacokinetics following administration of both oral and intravenous dose. It is also able to simulate repeat-dose administration and so is more relevant to the typical dosing regimen within the clinic. Unlike most competing products, chemPKTM uses a PBPK (physiologically-based pharmacokinetic) modelling approach which is a more robust technique for this purpose. The software is easy to implement and use. It operates on the freely available KNIME Analytics Platform for workflow management which facilitates integration with a wide range of other cheminformatics, analytics and modelling tools. Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'chemPKTM is a valuable virtual screening tool which can be used at an early stage prior to chemical synthesis of a molecule. The recently developed version 2 improves the relevance of chemPKTM to different dosing routes and regimens in the clinic. Cyprotex have built an impressive range of software products for predicting pharmacokinetic processes and toxicity which are now being utilised within the industry for directing chemistry and prioritising in vitro and in vivo screening.'
